[go: up one dir, main page]

AU2001294175A1 - Method of purifying antibody - Google Patents

Method of purifying antibody

Info

Publication number
AU2001294175A1
AU2001294175A1 AU2001294175A AU9417501A AU2001294175A1 AU 2001294175 A1 AU2001294175 A1 AU 2001294175A1 AU 2001294175 A AU2001294175 A AU 2001294175A AU 9417501 A AU9417501 A AU 9417501A AU 2001294175 A1 AU2001294175 A1 AU 2001294175A1
Authority
AU
Australia
Prior art keywords
purifying antibody
purifying
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294175A
Inventor
Emi Hosaka
Toyohide Shinkawa
Kenya Shitara
Kazuhisa Uchida
Motoo Yamasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of AU2001294175A1 publication Critical patent/AU2001294175A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001294175A 2000-10-06 2001-10-03 Method of purifying antibody Abandoned AU2001294175A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000308254 2000-10-06
JP2000-308254 2000-10-06
PCT/JP2001/008715 WO2002030954A1 (en) 2000-10-06 2001-10-03 Method of purifying antibody

Publications (1)

Publication Number Publication Date
AU2001294175A1 true AU2001294175A1 (en) 2002-04-22

Family

ID=18788598

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294175A Abandoned AU2001294175A1 (en) 2000-10-06 2001-10-03 Method of purifying antibody

Country Status (5)

Country Link
EP (1) EP1333032A4 (en)
JP (1) JPWO2002030954A1 (en)
AU (1) AU2001294175A1 (en)
CA (1) CA2424977C (en)
WO (1) WO2002030954A1 (en)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2807767B1 (en) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement MONOCLONAL ANTIBODIES ANTI-D
US20070122406A1 (en) 2005-07-08 2007-05-31 Xencor, Inc. Optimized proteins that target Ep-CAM
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2499816C (en) 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
BRPI0510674A (en) 2004-07-15 2007-12-26 Xencor Inc optimized fc variants
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
BRPI0517837A (en) 2004-11-12 2008-10-21 Xencor Inc fc variants with altered link to fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006089133A2 (en) 2005-02-15 2006-08-24 Duke University Anti-cd19 antibodies and uses in oncology
CA2599914C (en) 2005-03-01 2011-07-19 National University Of Corporation Hiroshima University Lectin isolated from bryopsis maxima that binds high-mannose-type sugar chains, used to purify chicken antibodies
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2012018687A1 (en) 2010-08-02 2012-02-09 Macrogenics, Inc. Covalent diabodies and uses thereof
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
PL1919503T3 (en) 2005-08-10 2015-04-30 Macrogenics Inc Identification and engineering of antibodies with variant fc regions and methods of using same
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
JP2009511018A (en) * 2005-10-06 2009-03-19 エムセラックス，エルエルシー Methods and compositions for anthrax spore glycoprotein as a vaccine
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8389688B2 (en) 2006-03-06 2013-03-05 Aeres Biomedical, Ltd. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP3456351A1 (en) * 2006-04-05 2019-03-20 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
ME01786B (en) 2006-08-14 2014-09-20 Xencor Inc Optimized antibodies that target cd19
HRP20150307T1 (en) * 2006-09-10 2015-04-24 Glycotope Gmbh USE OF HUMAN STATIONS ORIGINATING IN HUMAN LEUKEMIA FOR EXPRESSION OF ANTIBODIES
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
JP2010512306A (en) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー Polypeptides with enhanced anti-inflammatory properties and reduced cytotoxic properties and related methods
PT3199180T (en) 2007-03-08 2022-04-01 Univ Monash Epha3 antibodies for the treatment of solid tumors
BRPI0811466A2 (en) 2007-05-07 2014-10-14 Medimmune Llc ISOLATED ANTIBODY, NUCLEIC ACID, VECTOR, ISOLATED CELL, METHODS FOR PRODUCTING AN ANTIBODY, TO TREAT DISEASE OR DISORDER, TO TREAT OR PREVENT REJECTION IN A HUMAN TRANSPLANT PATIENT TO BE TURNED TO HUMAN, TO EXHAUST T CELLS EXPRESSING ICOS IN A HUMAN PATIENT, TO BREAK THE GERMINAL CENTER ARCHITECTURE IN A PRIMARY SECONDARY LYMPHID ORGAN, TO DEPLETE GERMAN CENTRAL LYMPHIDE ORGAN B CELLS WITH A PRIMATE BULTA IN CURRENT CLASSES IN A PRIMATE, AND, PHARMACEUTICAL COMPOSITION.
DK3072525T3 (en) 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
EP3392273A1 (en) 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
MX2009013816A (en) 2007-06-21 2010-02-24 Macrogenics Inc Covalent diabodies and uses thereof.
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP3211010A1 (en) 2007-12-21 2017-08-30 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r) - 173
ES2742268T3 (en) 2007-12-26 2020-02-13 Xencor Inc Fc variants with altered FcRn binding
MX2010007767A (en) 2008-01-18 2010-08-09 Medimmune Llc Cysteine engineered antibodies for site-specific conjugation.
HUE028958T2 (en) 2008-02-08 2017-01-30 Medimmune Llc Anti-IFNAR1 antibodies with reduced Fc ligand affinity
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
JP5785490B2 (en) 2008-04-02 2015-09-30 マクロジェニクス，インコーポレーテッド BCR complex-specific antibody and method of use thereof
ES2675730T3 (en) 2008-06-04 2018-07-12 Macrogenics, Inc. Antibodies with altered FcRn binding and methods of use thereof
KR101675901B1 (en) 2008-07-22 2016-11-15 제이-오일 밀스, 인코포레이티드 16 fucose 16 specific lectin
PL2853545T3 (en) 2008-09-17 2016-12-30 Antibody specific for IgE
MX2011002837A (en) 2008-09-19 2011-07-29 Medimmune Llc Antibodies directed to dll4 and uses thereof.
EP2358392B1 (en) 2008-11-12 2019-01-09 MedImmune, LLC Antibody formulation
CN102369021B (en) 2008-12-19 2016-09-07 宏观基因有限公司 Covalent diabodies and their uses
NZ594950A (en) 2009-03-06 2013-06-28 Kalobios Pharmaceuticals Inc Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
KR101808602B1 (en) 2009-10-07 2017-12-13 마크로제닉스, 인크. Fc REGION-CONTAINING POLYPEPTIDES THAT EXHIBIT IMPROVED EFFECTOR FUNCTION DUE TO ALTERATIONS OF THE EXTENT OF FUCOSYLATION, AND METHODS FOR THEIR USE
HUE033758T2 (en) 2009-10-26 2017-12-28 Hoffmann La Roche Method for the production of a glycosylated immunoglobulin
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
RU2012145183A (en) 2010-03-29 2014-05-10 Займворкс, Инк. ANTIBODIES WITH AN INCREASED OR REDUCED EFFECTIVE FUNCTION
JP2013534515A (en) 2010-06-01 2013-09-05 モナシュ ユニバーシティ Antibody to unprocessed receptor tyrosine kinase c-MET
AU2011268110B2 (en) 2010-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Anti-GD2 antibodies
CA2806252C (en) 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
BR112013004776A2 (en) 2010-08-27 2017-09-19 Stem Centrx Inc notum protein modulators and methods of use
CN103476429B (en) 2010-09-03 2016-08-24 施特姆森特克斯股份有限公司 Novel regulator and method of use
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
RU2604490C2 (en) 2010-11-05 2016-12-10 Займворкс Инк. DESIGN OF STABLE HETERODIMERIC ANTIBODY WITH MUTATIONS IN Fc DOMAIN
US20140302034A1 (en) 2010-12-08 2014-10-09 Stem Centrx, Inc. Novel modulators and methods of use
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-CD38 . antibody
SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use
HRP20170713T1 (en) 2011-04-19 2017-07-14 Merrimack Pharmaceuticals, Inc. BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODY
WO2012162068A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. METHOD FOR STRENGTHENING THE EFFECTORAL FUNCTION OF THE ORIGINAL POLYEPEPTIDE, ITS OPTIONS AND THEIR APPLICATIONS
US9475858B2 (en) 2011-07-08 2016-10-25 Momenta Pharmaceuticals, Inc. Cell culture process
WO2013013193A1 (en) 2011-07-20 2013-01-24 Zepteon, Incorporated Polypeptide separation methods
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
BR112014003110A2 (en) * 2011-08-10 2018-10-09 Lab Francais Du Fractionnement composition, method for producing a highly galactosylated population of antibodies, mammary gland epithelial cells and tramsgenic non-human mammal
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
CA2851534C (en) 2011-10-10 2023-02-14 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
KR102052774B1 (en) 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Stable heterodimeric antibody design with mutations in the fc domain
WO2013087789A1 (en) 2011-12-13 2013-06-20 Glykos Finland Ltd. Antibody isoform arrays and methods thereof
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2825191B1 (en) 2012-03-16 2019-08-28 University Health Network Soluble toso protein and its use in treating autoimmune disorders
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
US9663581B2 (en) 2012-04-25 2017-05-30 Momenta Pharmaceuticals, Inc. Modified glycoproteins
CA2872540A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
KR101566538B1 (en) 2012-06-08 2015-11-05 국립암센터 Novel epitope for switching to Th17 cell and use thereof
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
EP4397768A3 (en) 2012-07-26 2024-12-18 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
KR20200024345A (en) 2013-01-10 2020-03-06 젠맵 비. 브이 Human igg1 fc region variants and uses thereof
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
HRP20191865T1 (en) 2013-01-14 2020-01-10 Xencor, Inc. Novel heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
PL2953972T3 (en) 2013-02-05 2021-03-08 Engmab Sàrl Method for the selection of antibodies against bcma
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
BR112015019341A2 (en) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement ANTI-TNF-ALPHA ANTIBODY, COMPOSITION COMPRISING THE ANTIBODY, METHOD FOR PRODUCING A POPULATION OF ANTIBODIES, MAMMARY GLAND EPITHELIAL CELLS, TRANSGENIC NON-HUMAN MAMMAL, AND, MONOCLONAL ANTI-TNF ANTIBODY COMPOSITION
MX2015011712A (en) 2013-03-06 2016-04-04 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies.
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
CA3093606A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins for induction of t cells
EP3587448B1 (en) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
RU2680267C2 (en) 2013-03-15 2019-02-19 Мемориал Слоан Кеттеринг Кэнсер Сентер High-affinity anti-gd2 antibodies
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
ES2802274T3 (en) 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Sialylated glycoproteins
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
JP2016532100A (en) 2013-07-05 2016-10-13 ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ Affinity chromatography matrix
HUE055190T2 (en) 2013-10-11 2021-12-28 Oxford Bio Therapeutics Ltd Conjugated antibodies against ly75 for the treatment of cancer
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US20150252434A1 (en) 2014-03-07 2015-09-10 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
EP3954713A3 (en) 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
US20160060360A1 (en) 2014-07-24 2016-03-03 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CN116333153A (en) 2014-11-26 2023-06-27 森科股份有限公司 Heterodimeric antibodies that bind CD3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
EP3256164B1 (en) 2015-02-09 2020-03-25 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US20160280767A1 (en) 2015-03-23 2016-09-29 Lonza Ltd. Methods for controlling protein glycosylation
TWI716405B (en) 2015-05-07 2021-01-21 美商艾吉納斯公司 Anti-ox40 antibodies and methods of use thereof
EP3307319A4 (en) 2015-06-09 2019-05-22 Memorial Sloan Kettering Cancer Center ANTIBODIES SPECIFIC TO T-CELL RECEPTORS SPECIFIC TO EBV LATENT 2A MEMBRANE PROTEIN PRESENTED BY HUMAN HLA
FR3038517B1 (en) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY
PT3331910T (en) 2015-08-03 2020-03-24 Engmab Sarl Monoclonal antibodies against bcma
KR20180085800A (en) 2015-12-07 2018-07-27 젠코어 인코포레이티드 CD3 and heterodimeric antibodies that bind to PSMA
WO2017117218A1 (en) 2015-12-30 2017-07-06 Momenta Pharmaceuticals, Inc. Methods related to biologics
KR20230021765A (en) 2016-05-18 2023-02-14 젠맵 비. 브이 Antibodies and methods of use thereof in treatment of infectious disease
DK3468997T5 (en) 2016-06-08 2024-09-09 Xencor Inc Treatment of IgG4-related diseases with anti-CD9 antibodies cross-linked to CD32B
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific checkpoint inhibitor antibodies
KR20190020341A (en) 2016-06-28 2019-02-28 젠코어 인코포레이티드 Heterozygous antibodies that bind to somatostatin receptor 2
BR112019000544A2 (en) 2016-07-15 2019-04-24 Takeda Pharmaceutical Company Limited methods and materials for assessing response to plasmoblast- and plasma cell depletion therapies
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US20190270821A1 (en) 2016-09-13 2019-09-05 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
CN110214148A (en) 2016-10-14 2019-09-06 Xencor股份有限公司 Bispecific heterodimer fusion protein containing IL-15/IL-15R α Fc fusion protein and PD-1 antibody fragment
EP3535291A1 (en) 2016-11-01 2019-09-11 Genmab B.V. Polypeptide variants and uses thereof
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
EP3551225A1 (en) 2016-12-07 2019-10-16 Agenus Inc. Antibodies and methods of use thereof
TW201825515A (en) 2017-01-04 2018-07-16 美商伊繆諾金公司 Met antibodies and immunoconjugates and uses thereof
AU2018206015B2 (en) 2017-01-06 2019-05-30 Eutilex Co., Ltd. Anti-human 4-1 BB antibodies and use thereof
CA3052740A1 (en) 2017-02-10 2018-08-16 Eutilex Co., Ltd. Ifn-.gamma.-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
KR20250140128A (en) 2017-02-10 2025-09-24 젠맵 비. 브이 Polypeptide variants and uses thereof
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
UA128472C2 (en) 2017-08-25 2024-07-24 Файв Прайм Терапеутікс Інк. B7-H4 ANTIBODIES AND METHODS OF THEIR USE
JP7733443B2 (en) 2017-09-11 2025-09-03 モナシュ ユニバーシティー Binding protein for human thrombin receptor PAR4
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2020006322A (en) 2017-12-19 2020-09-18 Xencor Inc Engineered il-2 fc fusion proteins.
BR112020016986A2 (en) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. antibody formulations against b7-h4
CN111868089B (en) 2018-02-21 2025-08-22 戊瑞治疗有限公司 B7-H4 Antibody Dosing Regimen
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
CN112469477A (en) 2018-04-04 2021-03-09 Xencor股份有限公司 Heterodimeric antibodies binding to fibroblast activation proteins
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
MX2020011552A (en) 2018-05-03 2020-11-24 Genmab Bv Antibody variant combinations and uses thereof.
BR112020023373A2 (en) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugate, composition, and, use of a conjugate or composition
MY208638A (en) 2018-07-02 2025-05-21 Amgen Inc Anti-steap1 antigen-binding protein
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CA3106146A1 (en) 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
US20240254252A1 (en) 2018-07-13 2024-08-01 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
KR20210076025A (en) 2018-10-15 2021-06-23 파이브 프라임 테라퓨틱스, 인크. Cancer Combination Therapy
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
MX2021008030A (en) 2018-12-31 2021-08-05 Momenta Pharmaceuticals Inc METHODS TO PRODUCE USTEKINUMAB.
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
KR20210152472A (en) 2019-03-11 2021-12-15 메모리얼 슬로안 케터링 캔서 센터 CD22 antibody and methods of using the same
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
PE20230113A1 (en) 2020-01-16 2023-01-27 Genmab As FORMULATIONS OF ANTI-CD38 ANTIBODIES AND USES THEREOF
TWI896628B (en) 2020-03-26 2025-09-11 美國凡德貝爾大學 HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
IL297977A (en) 2020-05-17 2023-01-01 Astrazeneca Uk Ltd sars-cov-2 antibodies and methods for selecting and using them
JP7720871B2 (en) 2020-06-23 2025-08-08 ジアンスー カニョン ファーマシューティカル カンパニー リミテッド Anti-CD38 antibodies and uses thereof
CA3190280A1 (en) 2020-08-10 2022-02-17 Astrazeneca Uk Limited Sars-cov-2 antibodies for treatment and prevention of covid-19
KR102607909B1 (en) 2020-08-19 2023-12-01 젠코어 인코포레이티드 Anti-CD28 composition
CA3204628A1 (en) 2021-01-13 2022-07-21 John T. POIRIER Antibody-pyrrolobenzodiazepine derivative conjugate
US20240115721A1 (en) 2021-01-13 2024-04-11 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
JP2024511319A (en) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Heterodimeric antibody that binds to CD3 and CLDN6
JP2024509274A (en) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Heterodimeric antibody that binds to CD3 and GPC3
KR20240051280A (en) 2021-09-06 2024-04-19 젠맵 에이/에스 Antibodies capable of binding CD27, variants thereof and uses thereof
TW202342095A (en) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 Composition for treatment and prevention of covid-19
US20250101089A1 (en) 2022-01-24 2025-03-27 Cambridge Enterprise Limited Tau therapy
TW202342510A (en) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 Antibodies
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
AR132668A1 (en) 2023-05-12 2025-07-16 Genmab As ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND THEIR USES
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US6018032A (en) * 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
EP0994903B1 (en) * 1997-06-24 2005-05-25 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
JP4334141B2 (en) * 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity

Also Published As

Publication number Publication date
EP1333032A1 (en) 2003-08-06
WO2002030954A1 (en) 2002-04-18
CA2424977A1 (en) 2003-04-04
EP1333032A4 (en) 2005-03-16
CA2424977C (en) 2008-03-18
JPWO2002030954A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
AU2001294175A1 (en) Method of purifying antibody
AU2001240115A1 (en) Method for the preparation of tetrahydrobenzothiepines
AU2001246903A1 (en) Honeycomb structure and method for its manufacture
WO2002030986A3 (en) HUMANIZED ANTI-LT-β-R ANTIBODIES
AUPR208000A0 (en) Method of document searching
AU2548301A (en) Honeycomb structure and method for manufacture thereof
AU2002222081A1 (en) Method for making thermo-electric converters
AU2001238696A1 (en) Method of reducing defects
AU2002212754A1 (en) Honeycomb structure and method for manufacture thereof
AU2001241075A1 (en) Method of anticipating interaction between proteins
AUPR217700A0 (en) Methods for purification of lactose
AU2001294258A1 (en) Method of purifying plavastatin
AU2002214286A1 (en) Method of profiling protein
AU2001288092A1 (en) Method of crystallization
AU2001274137A1 (en) Method for purifying lactams
AU2002339305A1 (en) Method for purifying full blood
AU2002221492A1 (en) A method of purifying tetrodotoxin
AU2002231683A1 (en) Method of producing alk-3-ene-1-ols
AU2001213451A1 (en) Method for preparation of polycarbonates
AUPP385598A0 (en) Purification of antibodies
AU2001236047A1 (en) Method of separating and purifying protein
AU2002351532A1 (en) Method of sampling
AU2001284741A1 (en) Method for purification of acarbose
AU2001290731A1 (en) Structural prediction of allosterism
AU2001286268A1 (en) Method of forming complex